<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
Go Back

Biodesix Selected to Present at Multi-State Investor and Partnering Conference


WHAT: The Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC) Selection Committee has chosen Biodesix to present to more than 50 national investors and partnering entities at its 2011 conference September 21-22 in Denver. Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA). Biodesix, based in Broomfield, CO, is a fully integrated molecular diagnostic company developing products for personalized medicine that improve clinical decision making.

 WHEN: September 22, 2011, 9:40 a.m.

WHERE: The Brown Palace Hotel, 321 17th Street, Denver, CO

WHO: Frank Ronchetti, Chief Financial Officer, Biodesix

REGISTRATION:  Rocky Mountain Life Science Investor and Partnering Conference 


The Rocky Mountain region is the largest and most advanced area between both coasts, garnering more than $11.5 billion dollars in financings and acquisitions since the end of 2007. Engaging companies, investors and representatives from Arizona, Colorado, Montana, New Mexico, Oklahoma, Utah and Canada, the conference will open with a reception at the Colorado Governor’s Mansion September 21st and follow with a full day of company presentations and keynote speakers. The conference is an opportunity to showcase the vibrant life science community and quality investment opportunities in the region.

PRESENTING COMPANIES: Companies were selected from more than 50 applicants by a committee of investors, industry experts and representatives from partnering state bioscience associations.


Erik Clausen or Kena Hudson

Chempetitive Group for Biodesix




Topics: blood-based cancer test, cancer diagnostics, CBSA, Colorado BioScience Association, personalized medicine, Press Releases, RMLIPC, Rocky Mountain Life Science Investor and Partnerin, liquid biopsy, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC